Marinus A. Blankenstein

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

Maxime P. Look, Wim L.J. van Putten, Michael J. Duffy et al. · JNCI Journal of the National Cancer Institute · 2002 · 604 citations · Full text

Medicine, Biostatistics, Oncology +15

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

Niklas Mattsson, Ulf Andréasson, Staffan Persson et al. · Alzheimer s & Dementia · 2011 · 412 citations · Full text

Life Sciences, Neurology, Neuroscience +17

CSF biomarker variability in the Alzheimer's Association quality control program

Niklas Mattsson, Ulf Andréasson, Staffan Persson et al. · Alzheimer s & Dementia · 2013 · 385 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease

Cees Mulder, Nicolaas A. Verwey, Wiesje M. van der Flier et al. · Clinical Chemistry · 2009 · 344 citations · Full text

Medicine, Neurology, Neuroscience +17

Accuracy of 6 Routine 25-Hydroxyvitamin D Assays: Influence of Vitamin D Binding Protein Concentration

Annemieke C. Heijboer, Marinus A. Blankenstein, Ido P. Kema et al. · Clinical Chemistry · 2012 · 338 citations · Full text

Pharmacy, Nutritional Sciences, Chromatographic Analysis +14